AGEN got a substantial upfront from BMY last year for bispecific TIGIT pre-IND program too. Not much reaction as AGEN has other non-TIGIT projects. Theory sounds good. Perhaps NK and T cells exhaustion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.